Kiora Pharmaceuticals, Inc.
KPRX
$2.50
-$0.08-3.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 20.00K | 16.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 20.00K | 16.02M |
| Cost of Revenue | 3.71M | 3.72M | 3.97M | 3.97M | 4.90M |
| Gross Profit | -3.71M | -3.72M | -3.97M | -3.95M | 11.12M |
| SG&A Expenses | 5.75M | 5.61M | 5.55M | 5.74M | 5.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.46M | 9.34M | 9.52M | 9.70M | 10.44M |
| Operating Income | -9.46M | -9.34M | -9.52M | -9.68M | 5.58M |
| Income Before Tax | -12.12M | -7.11M | -9.91M | -9.86M | 5.66M |
| Income Tax Expenses | -1.28M | 1.43M | 2.08M | 2.19M | 2.07M |
| Earnings from Continuing Operations | -10.84 | -8.54 | -11.98 | -12.05 | 3.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.84M | -8.54M | -11.98M | -12.05M | 3.59M |
| EBIT | -9.46M | -9.34M | -9.52M | -9.68M | 5.58M |
| EBITDA | -9.43M | -9.32M | -9.51M | -9.67M | 5.60M |
| EPS Basic | -2.62 | -2.05 | -2.87 | -2.86 | 2.32 |
| Normalized Basic EPS | -1.31 | -1.23 | -1.27 | -1.25 | 1.93 |
| EPS Diluted | -2.62 | -2.06 | -2.87 | -2.86 | 1.12 |
| Normalized Diluted EPS | -1.31 | -1.23 | -1.27 | -1.25 | 1.18 |
| Average Basic Shares Outstanding | 16.67M | 16.71M | 16.64M | 16.82M | 15.49M |
| Average Diluted Shares Outstanding | 16.74M | 16.79M | 16.64M | 16.82M | 16.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |